Venture capital4 min read
AI drug development startup Pathos AI closes $237M investment
Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers.
By Maria DeutscherSiliconANGLE

Read the full story
Originally published by SiliconANGLE on Oct 23, 2026.
Comments
Sign in to join the discussion.